1
|
Maujean T, Ramanoudjame SM, Riché S, Le Guen C, Boisson F, Muller S, Bonnet D, Gulea M, Marchand P. Hetero-Diels-Alder and CuAAC Click Reactions for Fluorine-18 Labeling of Peptides: Automation and Comparative Study of the Two Methods. Molecules 2024; 29:3198. [PMID: 38999148 PMCID: PMC11243578 DOI: 10.3390/molecules29133198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2024] [Revised: 06/26/2024] [Accepted: 06/29/2024] [Indexed: 07/14/2024] Open
Abstract
Radiolabeled peptides are valuable tools for diagnosis or therapies; they are often radiofluorinated using an indirect approach based on an F-18 prosthetic group. Herein, we are reporting our results on the F-18 radiolabeling of three peptides using two different methods based on click reactions. The first one used the well-known CuAAC reaction, and the second one is based on our recently reported hetero-Diels-Alder (HDA) using a dithioesters (thia-Diels-Alder) reaction. Both methods have been automated, and the 18F-peptides were obtained in similar yields and synthesis time (37-39% decay corrected yields by both methods in 120-140 min). However, to obtain similar yields, the CuAAC needs a large amount of copper along with many additives, while the HDA is a catalyst and metal-free reaction necessitating only an appropriate ratio of water/ethanol. The HDA can therefore be considered as a minimalist method offering easy access to fluorine-18 labeled peptides and making it a valuable additional tool for the indirect and site-specific labeling of peptides or biomolecules.
Collapse
Affiliation(s)
- Timothé Maujean
- Université de Strasbourg, CNRS, Laboratoire d’Innovation Thérapeutique, LIT UMR 7200, F-67000 Strasbourg, France
| | - Sridévi M. Ramanoudjame
- Université de Strasbourg, CNRS, Laboratoire d’Innovation Thérapeutique, LIT UMR 7200, F-67000 Strasbourg, France
| | - Stéphanie Riché
- Université de Strasbourg, CNRS, Laboratoire d’Innovation Thérapeutique, LIT UMR 7200, F-67000 Strasbourg, France
| | - Clothilde Le Guen
- Université de Strasbourg, CNRS, Laboratoire d’Innovation Thérapeutique, LIT UMR 7200, F-67000 Strasbourg, France
- Inovarion, F-75005 Paris, France
| | - Frédéric Boisson
- Université de Strasbourg, CNRS, Institut Pluridisciplinaire Hubert Curien, IPHC UMR 7178, F-67000 Strasbourg, France
| | - Sylviane Muller
- Université de Strasbourg, CNRS, Biotechnologie et Signalisation Cellulaire UMR 7242, F-67000 Strasbourg, France
| | - Dominique Bonnet
- Université de Strasbourg, CNRS, Laboratoire d’Innovation Thérapeutique, LIT UMR 7200, F-67000 Strasbourg, France
| | - Mihaela Gulea
- Université de Strasbourg, CNRS, Laboratoire d’Innovation Thérapeutique, LIT UMR 7200, F-67000 Strasbourg, France
| | - Patrice Marchand
- Université de Strasbourg, CNRS, Institut Pluridisciplinaire Hubert Curien, IPHC UMR 7178, F-67000 Strasbourg, France
| |
Collapse
|
2
|
Metelerkamp Cappenberg T, De Schepper S, Vangestel C, De Lombaerde S, Wyffels L, Van den Wyngaert T, Mattis J, Gray B, Pak K, Stroobants S, Elvas F. First-in-human study of a novel cell death tracer [ 99mTc]Tc-Duramycin: safety, biodistribution and radiation dosimetry in healthy volunteers. EJNMMI Radiopharm Chem 2023; 8:20. [PMID: 37646865 PMCID: PMC10468453 DOI: 10.1186/s41181-023-00207-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Accepted: 08/23/2023] [Indexed: 09/01/2023] Open
Abstract
BACKGROUND Imaging of cell death can provide an early indication of treatment response in cancer. [99mTc]Tc-Duramycin is a small-peptide SPECT tracer that recognizes both apoptotic and necrotic cells by binding to phosphatidylethanolamine present in the cell membrane. Preclinically, this tracer has shown to have favorable pharmacokinetics and selective tumor accumulation early after the onset of anticancer therapy. In this first-in-human study, we report the safety, biodistribution and internal radiation dosimetry of [99mTc]Tc-Duramycin in healthy human volunteers. RESULTS Six healthy volunteers (3 males, 3 females) were injected intravenously with [99mTc]Tc-Duramycin (dose: 6 MBq/kg; 473 ± 36 MBq). [99mTc]Tc-Duramycin was well tolerated in all subjects, with no serious adverse events reported. Following injection, a 30-min dynamic planar imaging of the abdomen was performed, and whole-body (WB) planar scans were acquired at 1, 2, 3, 6 and 23 h post-injection (PI), with SPECT acquisitions after each WB scan and one low-dose CT after the first SPECT. In vivo 99mTc activities were determined from semi-quantitative analysis of the images, and time-activity curves were generated. Residence times were calculated from the dynamic and WB planar scans. The mean effective dose was 7.61 ± 0.75 µSv/MBq, with the kidneys receiving the highest absorbed dose (planar analysis: 43.82 ± 4.07 µGy/MBq, SPECT analysis: 19.72 ± 3.42 μGy/MBq), followed by liver and spleen. The median effective dose was 3.61 mSv (range, 2.85-4.14). The tracer cleared slowly from the blood (effective half-life of 2.0 ± 0.4 h) due to high plasma protein binding with < 5% free tracer 3 h PI. Excretion was almost exclusively renal. CONCLUSION [99mTc]Tc-Duramycin demonstrated acceptable dosimetry (< 5 mSv) and a favorable safety profile. Due to slow blood clearance, optimal target-to-background ratios are expected 5 h PI. These data support the further assessment of [99mTc]Tc-Duramycin for clinical treatment response evaluation. TRIAL REGISTRATION NCT05177640, Registered April 30, 2021, https://clinicaltrials.gov/study/NCT05177640 .
Collapse
Affiliation(s)
| | - Stijn De Schepper
- Department of Nuclear Medicine, Antwerp University Hospital (UZA), Edegem, Belgium
| | - Christel Vangestel
- Department of Nuclear Medicine, Antwerp University Hospital (UZA), Edegem, Belgium
- Molecular Imaging and Radiology (MIRA), University of Antwerp, Wilrijk, Belgium
| | - Stef De Lombaerde
- Department of Nuclear Medicine, Antwerp University Hospital (UZA), Edegem, Belgium
- Molecular Imaging and Radiology (MIRA), University of Antwerp, Wilrijk, Belgium
| | - Leonie Wyffels
- Department of Nuclear Medicine, Antwerp University Hospital (UZA), Edegem, Belgium
- Molecular Imaging and Radiology (MIRA), University of Antwerp, Wilrijk, Belgium
| | - Tim Van den Wyngaert
- Department of Nuclear Medicine, Antwerp University Hospital (UZA), Edegem, Belgium
- Molecular Imaging and Radiology (MIRA), University of Antwerp, Wilrijk, Belgium
| | - Jeffrey Mattis
- Molecular Targeting Technologies, Inc., West Chester, PA, USA
| | - Brian Gray
- Molecular Targeting Technologies, Inc., West Chester, PA, USA
| | - Koon Pak
- Molecular Targeting Technologies, Inc., West Chester, PA, USA
| | - Sigrid Stroobants
- Department of Nuclear Medicine, Antwerp University Hospital (UZA), Edegem, Belgium
- Molecular Imaging and Radiology (MIRA), University of Antwerp, Wilrijk, Belgium
| | - Filipe Elvas
- Department of Nuclear Medicine, Antwerp University Hospital (UZA), Edegem, Belgium.
- Molecular Imaging and Radiology (MIRA), University of Antwerp, Wilrijk, Belgium.
| |
Collapse
|
3
|
Zhang D, Gao M, Jin Q, Ni Y, Li H, Jiang C, Zhang J. Development of Duramycin-Based Molecular Probes for Cell Death Imaging. Mol Imaging Biol 2022; 24:612-629. [PMID: 35142992 DOI: 10.1007/s11307-022-01707-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2021] [Revised: 01/10/2022] [Accepted: 01/27/2022] [Indexed: 10/19/2022]
Abstract
Cell death is involved in numerous pathological conditions such as cardiovascular disorders, ischemic stroke and organ transplant rejection, and plays a critical role in the treatment of cancer. Cell death imaging can serve as a noninvasive means to detect the severity of tissue damage, monitor the progression of diseases, and evaluate the effectiveness of treatments, which help to provide prognostic information and guide the formulation of individualized treatment plans. The high abundance of phosphatidylethanolamine (PE), which is predominantly confined to the inner leaflet of the lipid bilayer membrane in healthy mammalian cells, becomes exposed on the cell surface in the early stages of apoptosis or accessible to the extracellular milieu when the cell suffers from necrosis, thus representing an attractive target for cell death imaging. Duramycin is a tetracyclic polypeptide that contains 19 amino acids and can bind to PE with excellent affinity and specificity. Additionally, this peptide has several favorable structural traits including relatively low molecular weight, stability to enzymatic hydrolysis, and ease of conjugation and labeling. All these highlight the potential of duramycin as a candidate ligand for developing PE-specific molecular probes. By far, a couple of duramycin-based molecular probes such as Tc-99 m-, F-18-, or Ga-68-labeled duramycin have been developed to target exposed PE for in vivo noninvasive imaging of cell death in different animal models. In this review article, we describe the state of the art with respect to in vivo imaging of cell death using duramycin-based molecular probes, as validated by immunohistopathology.
Collapse
Affiliation(s)
- Dongjian Zhang
- Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, Jiangsu Province, People's Republic of China.,Laboratories of Translational Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, Jiangsu Province, People's Republic of China
| | - Meng Gao
- Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, Jiangsu Province, People's Republic of China.,Laboratories of Translational Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, Jiangsu Province, People's Republic of China
| | - Qiaomei Jin
- Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, Jiangsu Province, People's Republic of China.,Laboratories of Translational Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, Jiangsu Province, People's Republic of China
| | - Yicheng Ni
- Theragnostic Laboratory, Campus Gasthuisberg, 3000, Leuven, Leuven, KU, Belgium
| | - Huailiang Li
- Department of General Surgery, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, 211200, Jiangsu Province, People's Republic of China
| | - Cuihua Jiang
- Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, Jiangsu Province, People's Republic of China. .,Laboratories of Translational Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, Jiangsu Province, People's Republic of China.
| | - Jian Zhang
- Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, Jiangsu Province, People's Republic of China. .,Laboratories of Translational Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, Jiangsu Province, People's Republic of China.
| |
Collapse
|